Medpace (MEDP) Announces Q4 Earnings Monday; Revenue Up 23.7% Y/Y, EPS Estimate $4.23

Clinical research tools and services provider Medpace Holdings (NASDAQ:MEDP) will report Q4 earnings Monday, February 15, 2026. Last quarter, the company posted revenues of $659.9 million, up 23.7% year-on-year, beating analyst revenue expectations by 2.7% and outperforming both organic revenue and full-year EPS guidance. For this quarter, the consensus is revenue of $686.1 million, a 27.9% year-on-year increase, versus $4.23 adjusted earnings per share. Analysts have maintained their estimates over the past 30 days despite four misses in the past two years. In the life sciences tools & services sector, IQVIA (IQV) revenue rose 10.3% YoY, beating expectations by 2.9%, while Azenta (AZNT) posted flat revenue but topped estimates by 1.1%. IQV declined 7.4% and Azenta fell 24.5% following respective earnings. Looking at Medpace, the stock is down 8.3% in the last month, while the sector is down 3.2% and the average analyst price target is $545.75 versus the current share price of $542.54.